The Diabetes Center of Beijing Puhua International Hospital focuses on innovative treatments for patients with Type-1 and Type-2diabetes. Beijing Puhua International Hospital combines Stem Cell Treatment with Traditional Chinese Medicine, as well as mainstream western approaches for diabetes. This combined methodology has been proven to be safe and effective. 70% of the patients who have been treated so far have had significant improvement, such as:
• More stable blood glucose
• A reduction in the need for medications (both insulin and oral diabetes medications)
• Improvement in symptoms secondary to diabetic issues, such as improved eyesight, improvement in peripheral neuropathy (such as less diabetic foot pain), better blood circulation, diminished or absent protein in the urine (proteinuria), and improved renal (kidney) function.
Dr. Chi Lian
Dr. Chi graduated from Heilongjiang Jiamusi Medical School, and has devoted herself to the treatment of diabetes since 1999. With more than 10 years of clinical experience, Dr. Chi has achieved great acumen in both the diagnosis and the treatment of diabetes. As one of China's leading experts in applied biological treatment for diabetes, Dr. Chi has achieved many positive outcomes, and is becoming a world leader of this exciting clinical frontier. Dr Chi expresses every confidence that applied medical bioscience will eventually defeat diabetes and other diseases, as understanding and clinical applications are refined.
Beginning in China, innovative biological treatment for diabetes, such as the biological program at Puhua International Hospitals-Temple of Heaven, are lighting the future of clinical medicine.
Stem Cell Treatment for Diabetes
MNCs and MSCs implantation are used in the treatment for diabetes, combined with conventional therapies.
“MNCs” is an abbreviation for mononuclear cells, better known as "monocytes." These cells are isolated from the patient’s own peripheral circulation. The term “MNCs” actually refers to a selected population comprised of several kinds of cells, including: EPCs (endothelial progenitor cells), MSCs (mesenchymal stem cells), MAPCs (multi-potent adult progenitor cells), MIAMI (marrow-isolated adult multi-lineage inducible cells), VSELs (very small embryonic-like cells), and HSC (hematopoietic cells).
MSCs (mesenchymal stem cells) are collected from the umbilical cord blood. Because MSCs are primitive cells, they have very low immunogenicity. Therefore, it is unnecessary to have matching tests before transplantation and patient doesn't need to take any immunosuppressive medicine after the treatment. That’s one of the advantages of MSCs.
1. Insulin/oral medication: the BPIH medical team will adjust the insulin or oral medicine dose in accordance to patients’ actual blood sugar levels both during and after the treatment. Patients should expect to reduce their insulin or oral medicine gradually;
2. Traditional Chinese Medicine (acupuncture, massage and/or Chinese herbal medicines);
3. Diabetic diet and counseling;
4. Exercise counseling.
Inclusion Criteria for Stem Cell Diabetes Therapy at BPIH
• Established diagnosis of either Type-1 or Type-2 Diabetes
• Age of greater than 3 years
• Absence of renal failure/patient not requiring dialysis therapy